Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MICHAEL J OLIVER

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1679501431
CMS profile
121491
Location
BEAVER, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$1,203.19

61 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,203.19 61

By paying entity

PY2025 · entire year · sorted by reported total

Page 1 of 2; records 1–50 of 61 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MICHAEL J OLIVER

NPI 1679501431 · CMS profile ID 121491

Allopathic & Osteopathic Physicians / Internal Medicine

BEAVER, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 2; records 1–50 of 61 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1679501431?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MICHAEL J OLIVER, NPI 1679501431, CMS profile ID 121491. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 61 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1679501431?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). MICHAEL J OLIVER, NPI 1679501431, CMS profile ID 121491. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 61 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1679501431?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
MICHAEL J OLIVER, NPI 1679501431, CMS profile ID 121491, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 61 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1679501431?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

61 matching records · $1,203.19 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 61 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 61.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Otsuka America Pharmaceutical, Inc. $20.0012/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227439397 CMS
Novo Nordisk Inc $20.9312/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188736155 CMS
GlaxoSmithKline, LLC. $13.4611/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190656908 CMS
GlaxoSmithKline, LLC. $26.7811/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190398910 CMS
Novo Nordisk Inc $20.1711/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188422074 CMS
Novo Nordisk Inc $20.0011/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1189015815 CMS
GlaxoSmithKline, LLC. $13.7911/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190786614 CMS
Amgen Inc. $14.7310/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227187956 CMS
Lilly USA, LLC $18.8310/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186764838 CMS
Otsuka America Pharmaceutical, Inc. $20.7710/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227439394 CMS
Novo Nordisk Inc $15.6210/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1189019231 CMS
Lundbeck LLC $24.4510/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251831382 CMS
GlaxoSmithKline, LLC. $17.6009/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191290201 CMS
Novo Nordisk Inc $14.1109/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188296973 CMS
GlaxoSmithKline, LLC. $20.0209/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191335456 CMS
PFIZER INC. $29.9609/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229503384 CMS
GlaxoSmithKline, LLC. $20.3209/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190605623 CMS
Novo Nordisk Inc $7.8009/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188589168 CMS
ABBVIE INC. $20.0609/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203380765 CMS
Teva Pharmaceuticals USA, Inc. $19.9108/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247444380 CMS
Otsuka America Pharmaceutical, Inc. $21.4308/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227439390 CMS
Novo Nordisk Inc $22.7908/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188569713 CMS
Lilly USA, LLC $23.0608/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186822512 CMS
Lilly USA, LLC $21.8607/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186773918 CMS
Recor Medical Inc $28.1307/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1245914984 CMS
PFIZER INC. $17.8907/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229113382 CMS
Sumitomo Pharma America, Inc. $24.5207/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1176699963 CMS
GlaxoSmithKline, LLC. $17.7007/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190599140 CMS
Novo Nordisk Inc $21.1607/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188759481 CMS
GlaxoSmithKline, LLC. $14.6707/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191609423 CMS
Phathom Pharmaceuticals, Inc. $19.1506/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1219362400 CMS
Otsuka America Pharmaceutical, Inc. $23.0806/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227439387 CMS
PFIZER INC. $14.6506/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229694842 CMS
GlaxoSmithKline, LLC. $25.0506/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191529041 CMS
Novo Nordisk Inc $19.8306/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188597637 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $19.6205/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222776644 CMS
Novo Nordisk Inc $23.0605/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188616351 CMS
GlaxoSmithKline, LLC. $22.7905/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191183048 CMS
GlaxoSmithKline, LLC. $14.1405/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191047233 CMS
AstraZeneca Pharmaceuticals LP $16.6705/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206951538 CMS
Lilly USA, LLC $22.4404/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186834366 CMS
Eisai Inc. $19.9904/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244499272 CMS
GlaxoSmithKline, LLC. $12.1204/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190900369 CMS
Otsuka America Pharmaceutical, Inc. $19.2304/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227439383 CMS
Novo Nordisk Inc $24.8704/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188243991 CMS
Abbott Laboratories $21.6504/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240921548 CMS
Novo Nordisk Inc $23.9203/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188516416 CMS
Novo Nordisk Inc $23.2703/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188540360 CMS
Lilly USA, LLC $23.6403/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186773916 CMS
GlaxoSmithKline, LLC. $23.5903/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190594869 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,982.16 111
PY2020 $387.82 28
PY2021 $1,408.56 66
PY2022 $1,192.77 60
PY2023 $1,343.06 63
PY2024 $1,223.14 62
PY2025 $1,203.19 61

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,083,959.47 12
PY2024 Recipient $43,914.50 5
PY2024 Principal investigator $1,015,962.54 15
PY2023 Recipient $195.00 1
PY2023 Principal investigator $828,848.21 14
PY2022 Recipient $34,661.00 4
PY2022 Principal investigator $514,412.47 14
PY2021 Principal investigator $507,716.92 33
PY2020 Recipient $5,278.97 8
PY2020 Principal investigator $291,944.00 17
PY2019 Recipient $10,899.97 2
PY2019 Principal investigator $442,530.95 27

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

29 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GlaxoSmithKline, LLC. $2,010.02 12/12/2019 Non-covered Recipient Entity
HERITAGE VALLEY MEDICAL GROUP INC
A 28-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROU No dispute reported 06/30/2026 709081257
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,183.27 12/01/2019 Non-covered Recipient Entity
Heritage Valley Medical Group
Phase II study of BI456906 in Patients with T2DM O No dispute reported 06/30/2026 704146655
Principal investigator 1 Eli Lilly and Company $36,490.00 10/29/2019 Non-covered Recipient Entity
TRI STATE MEDICAL GROUP INC
A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL COMPARING EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS SEMAGLUTIDE ONCE WEEKLY AS ADD-ON THERAPY TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES No dispute reported 06/30/2026 654298735
Principal investigator 1 SANOFI US SERVICES INC. $3,180.00 09/30/2019 Non-covered Recipient Entity
Heritage Valley Medical Group Inc
A 52-week Randomized, Double-blind, Double-dummy, Active and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Glimepiride or Place No dispute reported 06/30/2026 691569969
Principal investigator 1 GlaxoSmithKline, LLC. $2,870.10 09/25/2019 Non-covered Recipient Entity
HERITAGE VALLEY MEDICAL GROUP INC
A 28-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROU No dispute reported 06/30/2026 669964713
Principal investigator 1 Eli Lilly and Company $56,853.00 08/13/2019 Non-covered Recipient Entity
TRI STATE MEDICAL GROUP INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL COMPARING THE EFFICACY AND SAFETY OF THREE TIRZEPATIDE DOSES VERSUS PLACEBO IN PATIENTS WITH TYPE 2 DIABETES, INADEQUATELY CONTROLLED WITH DIET AND EXERCISE ALONE No dispute reported 06/30/2026 654297445
Principal investigator 1 Eli Lilly and Company $4,597.04 07/05/2019 Non-covered Recipient Entity
TRI STATE MEDICAL GROUP INC
A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL COMPARING EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS SEMAGLUTIDE ONCE WEEKLY AS ADD-ON THERAPY TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES No dispute reported 06/30/2026 654296487
Principal investigator 1 SANOFI US SERVICES INC. $3,481.00 06/25/2019 Non-covered Recipient Entity
Heritage Valley Medical Group Inc
A 52-week Randomized, Double-blind, Double-dummy, Active and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Glimepiride or Place No dispute reported 06/30/2026 691559605
Principal investigator 1 GlaxoSmithKline, LLC. $7,737.55 06/20/2019 Non-covered Recipient Entity
HERITAGE VALLEY MEDICAL GROUP INC
A 28-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROU No dispute reported 06/30/2026 669963847
Principal investigator 1 Janssen Research & Development, LLC $623.00 06/17/2019 Non-covered Recipient Entity
HERITAGE VALLEY MEDICAL GROUP INC
A Randomized, Double-blind Placebo-controlled, Parallel-group, Multicenter, Dose-ranging Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Severely Obese Subjects with Type 2 Diabetes Mellitus No dispute reported 06/30/2026 654249913
Principal investigator 1 Eli Lilly and Company $64,658.00 06/11/2019 Non-covered Recipient Entity
TRI STATE MEDICAL GROUP INC
A RANDOMIZED, PHASE 3, OPEN-LABEL TRIAL COMPARING THE EFFECT OF LY3298176 VERSUS TITRATED INSULIN DEGLUDEC ON GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES No dispute reported 06/30/2026 654298485
Principal investigator 1 Janssen Research & Development, LLC $10,161.00 06/03/2019 Non-covered Recipient Entity
HERITAGE VALLEY MEDICAL GROUP INC
A Randomized, Double-blind Placebo-controlled, Parallel-group, Multicenter, Dose-ranging Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Severely Obese Subjects with Type 2 Diabetes Mellitus No dispute reported 06/30/2026 654249915
Principal investigator 1 Janssen Research & Development, LLC $3,249.00 05/23/2019 Non-covered Recipient Entity
Heritage Vly Hlth
A Randomized Double Blind, Placebo Group, Two-Arm, Multicenter study to Assess Efficacy of Canagliflozin on End Stage Kidney Disease and Vascular Death in Subjects with Type 2 Diabetes Mellitus and nephropathy No dispute reported 06/30/2026 654250105
Principal investigator 1 Eli Lilly and Company $6,087.92 05/07/2019 Non-covered Recipient Entity
TRI STATE MEDICAL GROUP INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL COMPARING THE EFFICACY AND SAFETY OF THREE TIRZEPATIDE DOSES VERSUS PLACEBO IN PATIENTS WITH TYPE 2 DIABETES, INADEQUATELY CONTROLLED WITH DIET AND EXERCISE ALONE No dispute reported 06/30/2026 654298733
Principal investigator 1 Janssen Research & Development, LLC $2,632.00 04/15/2019 Non-covered Recipient Entity
HERITAGE VALLEY MEDICAL GROUP INC
A Randomized, Double-blind Placebo-controlled, Parallel-group, Multicenter, Dose-ranging Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Severely Obese Subjects with Type 2 Diabetes Mellitus No dispute reported 06/30/2026 654249911
Principal investigator 1 Eli Lilly and Company $126,057.00 04/09/2019 Non-covered Recipient Entity
TRI STATE MEDICAL GROUP INC
A STUDY OF TIRZEPATIDE (LY3298176) ONCE A WEEK VERSUS INSULIN GLARGINE ONCE A DAY IN PARTICIPANTS WITH TYPE 2 DIABETES AND INCREASED CARDIOVASCULAR RISK No dispute reported 06/30/2026 654297443
Recipient Eli Lilly and Company $531.97 04/02/2019 Covered Recipient Physician A STUDY OF TIRZEPATIDE (LY3298176) ONCE A WEEK VERSUS INSULIN GLARGINE ONCE A DAY IN PARTICIPANTS WITH TYPE 2 DIABETES AND INCREASED CARDIOVASCULAR RISK No dispute reported 06/30/2026 654283793
Principal investigator 1 Eli Lilly and Company $742.00 03/26/2019 Non-covered Recipient Entity
TRI STATE MEDICAL GROUP INC
A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND COMPARISON OF LY900014 TO INSULIN LISPRO, BOTH IN COMBINATION WITH INSULIN GLARGINE OR INSULIN DEGLUDEC IN ADULTS WITH TYPE 2 DIABETES PRONTO-T2D No dispute reported 06/30/2026 654297987
Principal investigator 1 GlaxoSmithKline, LLC. $6,123.62 03/26/2019 Non-covered Recipient Entity
HERITAGE VALLEY MEDICAL GROUP INC
A 28-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROU No dispute reported 06/30/2026 669958907
Principal investigator 1 Novo Nordisk AS $8,218.40 03/26/2019 Non-covered Recipient Entity
HERITAGE VALLEY INTERNAL MEDICINE
NN9068-4228 No dispute reported 06/30/2026 692451005
Principal investigator 1 SANOFI US SERVICES INC. $6,015.00 03/21/2019 Non-covered Recipient Entity
Heritage Valley Medical Group Inc
A 52-week Randomized, Double-blind, Double-dummy, Active and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Glimepiride or Place No dispute reported 06/30/2026 691546011
Principal investigator 1 Eli Lilly and Company $9,569.25 03/15/2019 Non-covered Recipient Entity
TRI STATE MEDICAL GROUP INC
A RANDOMIZED, PHASE 3, OPEN-LABEL TRIAL COMPARING THE EFFECT OF LY3298176 VERSUS TITRATED INSULIN DEGLUDEC ON GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES No dispute reported 06/30/2026 654296485
Principal investigator 1 Eli Lilly and Company $28,622.00 03/12/2019 Non-covered Recipient Entity
TRI STATE MEDICAL GROUP INC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL ARM STUDY OF THE EFFICACY AND SAFETY OF INVESTIGATIONAL DULAGLUTIDE DOSES WHEN ADDED TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS No dispute reported 06/30/2026 654298949
Principal investigator 1 Janssen Research & Development, LLC $7,705.00 03/04/2019 Non-covered Recipient Entity
HERITAGE VALLEY MEDICAL GROUP INC
A Randomized, Double-blind Placebo-controlled, Parallel-group, Multicenter, Dose-ranging Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Severely Obese Subjects with Type 2 Diabetes Mellitus No dispute reported 06/30/2026 654249905
Principal investigator 1 Janssen Research & Development, LLC $12,677.00 02/04/2019 Non-covered Recipient Entity
HERITAGE VALLEY MEDICAL GROUP INC
A Randomized, Double-blind Placebo-controlled, Parallel-group, Multicenter, Dose-ranging Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Severely Obese Subjects with Type 2 Diabetes Mellitus No dispute reported 06/30/2026 654249909
Principal investigator 1 Eli Lilly and Company $13,730.60 01/31/2019 Non-covered Recipient Entity
TRI STATE MEDICAL GROUP INC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL ARM STUDY OF THE EFFICACY AND SAFETY OF INVESTIGATIONAL DULAGLUTIDE DOSES WHEN ADDED TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS No dispute reported 06/30/2026 654297989
Principal investigator 1 Eli Lilly and Company $4,415.18 01/23/2019 Non-covered Recipient Entity
TRI STATE MEDICAL GROUP INC
A STUDY OF TIRZEPATIDE (LY3298176) ONCE A WEEK VERSUS INSULIN GLARGINE ONCE A DAY IN PARTICIPANTS WITH TYPE 2 DIABETES AND INCREASED CARDIOVASCULAR RISK No dispute reported 06/30/2026 654298487
Recipient Eli Lilly and Company $10,368.00 01/15/2019 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND, PARALLEL ARM STUDY OF THE EFFICACY AND SAFETY OF INVESTIGATIONAL DULAGLUTIDE DOSES WHEN ADDED TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS No dispute reported 06/30/2026 654282707
Principal investigator 1 Janssen Research & Development, LLC $12,843.00 01/07/2019 Non-covered Recipient Entity
HERITAGE VALLEY MEDICAL GROUP INC
A Randomized, Double-blind Placebo-controlled, Parallel-group, Multicenter, Dose-ranging Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Severely Obese Subjects with Type 2 Diabetes Mellitus No dispute reported 06/30/2026 654249907